B
Bull
Bull · 25%MRKR
$0.37
Szenariopreis
$1.370
-0.084 (-6.16%)Zum Schluss
Loading chart…
- High
- 1.500
- Open
- 1.500
- VWAP
- 1.41
- Vol
- 84.78K
- Mkt Cap
- 43.08M
- Low
- 1.350
- Amount
- 119.26K
- EV/EBITDA, TTM
- -0.24
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
AI analysis of Marker Therapeutics Inc (MRKR)
buyMarker Therapeutics Inc appears to be a good buy right now due to its recent positive earnings report, where it beat EPS expectations by $0.15, and its strong projected trajectory of +133.06%. However, the main risk is the recent decline in stock price, which dropped 14.28% following a clinical update, indicating volatility.
Bewertungskennzahlen
The current forward P/E ratio for Marker Therapeutics Inc (MRKR) is 0.00, compared to its 5-year average forward P/E of -1.49.
Alphio AI Price Scenarios for MRKR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MRKR
Event-Zeitleiste
News
9.503-18seekingalphaMarker Therapeutics Reports Better-Than-Expected Earnings
2.012-19NASDAQ.COMBiotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
3.512-11GlobenewswireMerakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium
9.511-14NewsfilterMarker Therapeutics Announces Financial Results for Q3 2025 and Shares Business Developments
- 9.011-03Newsfilter
Marker Therapeutics to Present MT-601 Data for Relapsed Non-Hodgkin and Hodgkin Lymphoma at 67th ASH Annual Meeting
MRKR FAQ — answered by Alphio AI
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Marker Therapeutics Inc appears to be a good buy right now due to its recent positive earnings report, where it beat EPS expectations by $0.15, and its strong projected trajectory of +133.06%. However, the main risk is the recent decline in stock price, which dropped 14.28% following a clinical update, indicating volatility.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.